GNRHR2 and ovarian carcinoma: In another study, anti-proliferative effects of triptorelin were abolished after GnRHR1 knockdown in ovarian cancer cells (EFO-21 and OVCAR-3), but effects of GnRH2 and the pan GnRHR antagonist, cetrorelix (binds both GnRHR1 and GnRHR2 (70)), persisted (18).